Coherus BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coherus BioSciences, Inc.
Sandoz has truly established its position as the frontrunner in the denosumab race after a Canadian approval, but the path to the US market has been hindered by a lawsuit from the originator Amgen.
Pink Sheet’s Drug Review Profile explores Amgen’s Wezlana, an interchangeable biosimilar to Janssen’s Stelara. FDA determined late in the review that switching studies generally would not be needed for interchangeable ustekinumab products, prompting Amgen to seek the designation.
CDER missed six goal dates among its 2023 novel approvals, reflecting safety concerns as well as pandemic-related inspection delays; Duchenne muscular dystrophy accelerated approval disagreements caused the biologics center’s lone missed goal.
Coherus BioSciences revealed that it has shipped nearly 200,000 doses of its Lucentis biosimilar Cimerli, as it pondered from where to grab further market share in 2024 at the J.P. Morgan Annual Healthcare Conference.
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- InteKrin Therapeutics, Inc.
- Coherus Intermediate Corp
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.